Tags

Type your tag names separated by a space and hit enter

2008 Clinical approach to irritable bowel syndrome.
Minerva Gastroenterol Dietol. 2008 Sep; 54(3):251-7.MG

Abstract

Irritable bowel syndrome (IBS), as defined by Rome III diagnostic criteria, affects 10-20% of the general population, with women 20-40 years old accounting for the majority of patients. Although variable and intermittent, IBS symptoms may persist for many years. Repeated referrals for medical consultation and diagnostic studies generate huge healthcare costs. Since there is no evidence that IBS leads to more severe gastrointestinal disorders, in absence of alarm symptoms or signs, an invasive diagnostic algorithm is not indicated. Optimal treatment for IBS still needs to be defined. The clinical approach is based on treatment of the prevalent symptom. When pain predominates, antispasmodics are the first choice. In case of diarrhea, loperamide is useful for reducing bowel frequency. Soluble fiber represents the first option in subjects with IBS and constipation or mixed IBS. Dietary integrators composed of probiotics and serotonin precursors are a promising therapeutic option.

Authors+Show Affiliations

Unit of Gastro-epatology, San Giovanni Battista Hospital, Turin, Italy. mastegiano@molinette.piemonte.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18614974

Citation

Astegiano, M, et al. "2008 Clinical Approach to Irritable Bowel Syndrome." Minerva Gastroenterologica E Dietologica, vol. 54, no. 3, 2008, pp. 251-7.
Astegiano M, Pellicano R, Sguazzini C, et al. 2008 Clinical approach to irritable bowel syndrome. Minerva Gastroenterol Dietol. 2008;54(3):251-7.
Astegiano, M., Pellicano, R., Sguazzini, C., Berrutti, M., Simondi, D., Reggiani, S., & Rizzetto, M. (2008). 2008 Clinical approach to irritable bowel syndrome. Minerva Gastroenterologica E Dietologica, 54(3), 251-7.
Astegiano M, et al. 2008 Clinical Approach to Irritable Bowel Syndrome. Minerva Gastroenterol Dietol. 2008;54(3):251-7. PubMed PMID: 18614974.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 2008 Clinical approach to irritable bowel syndrome. AU - Astegiano,M, AU - Pellicano,R, AU - Sguazzini,C, AU - Berrutti,M, AU - Simondi,D, AU - Reggiani,S, AU - Rizzetto,M, PY - 2008/7/11/pubmed PY - 2009/2/24/medline PY - 2008/7/11/entrez SP - 251 EP - 7 JF - Minerva gastroenterologica e dietologica JO - Minerva Gastroenterol Dietol VL - 54 IS - 3 N2 - Irritable bowel syndrome (IBS), as defined by Rome III diagnostic criteria, affects 10-20% of the general population, with women 20-40 years old accounting for the majority of patients. Although variable and intermittent, IBS symptoms may persist for many years. Repeated referrals for medical consultation and diagnostic studies generate huge healthcare costs. Since there is no evidence that IBS leads to more severe gastrointestinal disorders, in absence of alarm symptoms or signs, an invasive diagnostic algorithm is not indicated. Optimal treatment for IBS still needs to be defined. The clinical approach is based on treatment of the prevalent symptom. When pain predominates, antispasmodics are the first choice. In case of diarrhea, loperamide is useful for reducing bowel frequency. Soluble fiber represents the first option in subjects with IBS and constipation or mixed IBS. Dietary integrators composed of probiotics and serotonin precursors are a promising therapeutic option. SN - 1121-421X UR - https://www.unboundmedicine.com/medline/citation/18614974/2008_Clinical_approach_to_irritable_bowel_syndrome_ L2 - http://www.diseaseinfosearch.org/result/3876 DB - PRIME DP - Unbound Medicine ER -